Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature.

Doxorubicin (Adriamycin) is an effective antitumour drug. Its major side-effect, cardiotoxicity, is markedly reduced by giving it as a continuous infusion, as illustrated by a case history and review of the literature.